Signs and Symptoms

Neoplasms

Neoplasms by Site

Fatigue

Breast Neoplasms

Breast Diseases

Guarana extract 50mg q12 hours for 21 days

Guarana extract

Faculdade de Medicina do ABC

Guarana (Paullinia Cupana) for Breast Cancer Chemotherapy-related Fatigue

Guaraná ("Paullinia Cupana") for Chemotherapy Related Fatigue in Breast Cancer Patients: Results Of A Pilot Double Blind Randomized Study

Auro Del Giglio, MD, PhD

Patients will receive Capecitabine 625 mg/m2 bid PO for 14 days to be repeated every 21 days until progression in combination with aromatase inhibitor if postmenopausal, addition of LHRH agonist will be added if premenopausal.

Patients will receive aromatase inhibitors ( letrozole 2.5 mg PO per day or Anastrozole 1 mg PO per day or aromasin 25 mg PO per day) if post-menopausal, if premenopausal leutnising hormone releasing hormone (LHRH) agonist will be added to the aromatase inhibitor.

Metastatic Breast Cancer

participants are chosen on self-representation of gender identity

Capecitabine 625 mg/m2 bid PO for 14 days to be repeated every 21 days until progression in combination with aromatase inhibitor if postmenopausal, addition of LHRH agonist will be added if premenopausal.

Capecitabine plus aromatase inhibitor

aromatase inhibitors ( letrozole 2.5 mg PO per day or Anastrozole 1 mg PO per day or aromasin 25 mg PO per day) if post-menopausal, if premenopausal leutnising hormone releasing hormone (LHRH) agonist will be added to the aromatase inhibitor

A.I.

Sun Yat-sen University (2016) Metronomic Capecitabine Plus Aromatase Inhibitor for First Line Treatment in HR(+), Her2(-) Metastatic Breast Cancer - Full Text View - ClinicalTrials.gov

Clinical oncology department, Faculty of medicine, Ain Shams University

Capecitabine in Combination With Aromatase Inhibitor Versus Aromatase Inhibitors, in Hormonal Receptor Positive Recurrent or Metastatic Breast Cancer Patients, Randomized Controlled Study

Capecitabine in Combination With Aromatase Inhibitor Versus Aromatase Inhibitors, in Hormonal Receptor Positive Recurrent or Metastatic Breast Cancer Patients, Randomized Controlled Study (CONCEPT Trial)

Time from randomization to the first documentation of objective tumor progression or to death due to any cause or Intolerable toxicity.

Detailed Description and grading of adverse events

Hesham Elghazaly,MD

professor

Ain Shams University

Dexmedetomidine 0.2 to 1.1 mcg/kg/hr by continuous subcutaneous infusion for up to 10 days

Midazolam 10 to 100 mcg/kg/hr by continuous subcutaneous infusion for up to 10 days

Pain Intractable

Delirium

Dyspnea

Nausea

Study drugs will be administered by continuous subcutaneous infusion using a weight based protocol at a rate between 1.0 to 5.5 mL/hr.
The study drug will be started at a rate of 1.0 mL/hr.
The infusion rate is incremented by 0.5 ml/hr every 30 minutes until acceptable symptom control, bradycardia (heart rate < 40) or hypotension (systolic blood pressure < 80) prevent further increase or maximum infusion rate of 5.5 ml/hr, whichever comes first. Achievement of acceptable symptom control will be defined, for purposes of this trial, as a consensus between reports from patient, family care giver and attending registered nurse

Dexmedetomidine

Midazolam

Abbotsford Regional Hospital and Cancer Center

Pilot Study Comparing Treatment With Dexmedetomidine to Midazolam for Symptom Control in Advanced Cancer Patients

Dexmedetomidine Compared to Midazolam for Symptom Control in Advanced Cancer Patients: A Pilot Randomized Controlled Trial (RCT)

Sample size determination for significant improvement in:
Pain
Dyspnea
Nausea
Delirium
Rousability

Pain will be evaluated using the Edmonton Symptom Assessment Scale (ESASr)

Dyspnea will be evaluated using the Edmonton Symptom Assessment Scale (ESASr)

Nausea will be evaluated using the Edmonton Symptom Assessment Scale (ESASr)

Delirium will be assessed using the Delirium Rating Scale-Revised-98 (DRS-R-98)

Rousability will be measured using the Richmond Agitation and Sedation Scale (RASS)

Acceptable symptom control of the difficult to control or intractable symptoms of pain, dyspnea, nausea or delirium will be assessed by a two part question addressed to each of subject, family member and assigned palliative care nurse. Subjective responses will be collected from each as binary variables (0/1) with two positive responses indicating acceptable symptom control overall.

This information will be used to determine accrual rate. The accrual rate and the primary outcome measure of number needed to recruit will be used to determine the number of sites required for a multi-center double blind randomized controlled Phase III trial comparing dexmedetomidine to midazolam for symptom control in advanced cancer patients.

bola/krūties vėžys

Guarana (Paullinia Cupana) for Breast Cancer Chemotherapy-related Fatigue

Capecitabine in Combination With Aromatase Inhibitor Versus Aromatase Inhibitors, in Hormonal Receptor Positive Recurrent or Metastatic Breast Cancer Patients, Randomized Controlled Study

Pilot Study Comparing Treatment With Dexmedetomidine to Midazolam for Symptom Control in Advanced Cancer Patients

Išsamiausia vaistinių žolelių duomenų bazė, paremta mokslu